Cymbiotika Liposomal NAD+ Review: The Only Human Study Used 3 Times the Dose

Brand Guides
November 15, 2026

NAD+ is the most hyped molecule in the longevity world, and the supplement built around it has the thinnest evidence of any product in this series so far. The pitch is seductive. NAD+ levels fall as we age, NAD+ powers the mitochondria and the DNA repair enzymes, so topping it up should slow aging. The problem is the delivery. NAD+ is a large, charged molecule that the gut breaks down, which is why most of the research uses precursors like NMN and NR, smaller building blocks the body converts into NAD+ inside the cell. Cymbiotika sells the direct approach instead: 300 mg of actual NAD+ wrapped in liposomes, plus a supporting cast meant to slow NAD+ breakdown and help the body make more of it. The question is whether any of that survives contact with human evidence. The honest answer is that almost none of it has been tested, and the one study that exists used a different product at more than three times the dose.

Disclosure: I'm affiliated with Cymbiotika, but I only recommend things I can actually stand behind so here's my honest breakdown.

The short answer

There is exactly one published human study of liposomal NAD+ itself. It had 14 people, no placebo group, no randomisation, and it was funded by the company that makes the product tested. It used 1,000 mg a day for two weeks and found intracellular NAD+ rose about 64 percent. This product has 300 mg per packet, a third of that dose, and it is a different formula. The brand claims up to 3 times higher absorption, but no study on the page supports that number, and no trial has compared this product against a standard NAD+ supplement or against NMN or NR. The precursors, NMN and NR, have real human trials showing they raise blood NAD+, even though their effects on actual health outcomes are mixed. The supporting ingredients are sensibly chosen. Niacin is a direct NAD+ precursor, TMG donates methyl groups that NAD+ metabolism consumes, apigenin blocks the CD38 enzyme that drains NAD+ in mice, and the caffeine explains why people feel energy on day one. None of that has been tested in this combination in people. At about $2 a packet on the brand site, you are paying for a plausible formula and a convenient packet, not for proven results.

The research gap this product actually fills

Two different gaps sit behind this formula, and it is important to keep them apart. The first is the delivery gap. NAD+ itself is hard to deliver by mouth. It is a big molecule, it carries a charge, and the gut and liver break it down before it reaches cells. That is why the field moved to precursors. NR and NMN are smaller, they have dedicated transport routes, and dozens of human trials show they raise blood NAD+ markers. Liposomal wrapping is supposed to solve the delivery problem by shielding the NAD+ through digestion, the same trick that worked for vitamin C and glutathione. But the trick has to be proven for each molecule, because a liposome that helps vitamin C does not automatically help NAD+. The second gap is the evidence gap. Even for the precursors, the 2026 systematic review found that raising blood NAD+ reliably does not mean improving health. Functional, metabolic, and vascular outcomes were mixed and often null across 33 human studies. So this product faces two unanswered questions at once. Does liposomal NAD+ reach the cell, and does raising NAD+ change anything that matters? The study record answers neither for this product.

The 2026 study: the only human trial of liposomal NAD+

The study was published in March 2026 in Naturopathic Doctor News and Review. Fourteen people took 1,000 mg of a liposomal NAD+ preparation called CELLg8 every day for two weeks, then switched to a second liposomal preparation at the same dose after a three-week washout. Intracellular NAD+ was measured from finger-prick dried blood spots at the start and end of each two-week period. Average intracellular NAD+ rose about 64 percent from baseline in both periods, a statistically significant change.

That is a real result, and it is the only one the field has. It is also a weak design for the claims built on it. There was no placebo group and no randomisation, so there is no way to separate the supplement from a placebo effect or from natural variation. Fourteen people is a pilot, not a trial. The study was funded by CELLg8, the lead author owns the company, and the other two authors work for it. One participant taking an SSRI antidepressant dropped out after reporting worse depressive symptoms. And the dose matters most of all. The study used 1,000 mg a day. This product has 300 mg per packet. Nobody has tested whether 300 mg of liposomal NAD+ raises intracellular NAD+ at all, and nobody has tested this brand's formula in people.

What the precursors prove, and what they do not

If you want the strongest evidence for raising NAD+, it belongs to the precursors, not to direct NAD+. A 2026 systematic review in Ageing Research Reviews looked at 113 studies published between 2010 and November 2025, including 33 human intervention studies. Oral NR and NMN consistently raised NAD+ related metabolites in blood and cells and were generally well tolerated over weeks to months. But effects on functional, metabolic, vascular, and healthspan outcomes were mixed and often null, and the authors concluded that clinical efficacy for anti-aging or wellness outcomes is not established. The review also found no eligible outcome trial of NAD+ itself given by infusion or injection for anti-aging or wellness.

The individual trials tell the same story. In a 60-day randomised trial of 80 healthy adults aged 40 to 65, NMN at 300, 600, and 900 mg a day raised blood NAD+ in a dose-dependent way, and the 600 and 900 mg groups walked further in a six-minute test than the placebo group. In a 10-week trial, 250 mg of NMN a day improved muscle insulin sensitivity in postmenopausal women with prediabetes and overweight. A 2026 meta-analysis of 15 randomised NMN trials found no significant effect on body weight, fasting glucose, HbA1c, blood lipids, or systolic blood pressure, though diastolic pressure fell slightly. A 52-week phase 3 trial of NR in 410 people with early Parkinson's disease did not show the expected benefit. NR roughly doubled blood NAD+ in a small pilot of people with mild cognitive impairment, but cognition, cerebral blood flow, and blood pressure did not improve. NR did improve walking speed in people over 50 with peripheral artery disease in a 2024 study. The pattern is consistent. Raising the marker is easy. Changing health is not proven.

The supporting cast: smart on paper, unproven in combination

This is where the formula gets interesting, and where honesty demands a split verdict. Each supporting ingredient has a reason to be there. Niacin, at 7 mg or 43 percent of the daily value, is a direct NAD+ precursor through the Preiss-Handler pathway, and the dose is well below the 50 mg range where flushing usually starts. TMG, at 1,000 mg, is a methyl donor, and NAD+ metabolism consumes methyl groups, so topping them up is a sensible hedge, and 1,000 mg matches the doses used in TMG studies. Apigenin, at 50 mg, blocks CD38, the enzyme that rises with age and drains NAD+, and it raised NAD+ in mice. No human dose has been established. Caffeine, at 20 mg from green coffee bean extract, is about a fifth of a cup of coffee, and it is the most likely reason the brand promises energy you can measure on day one. Lutemax 2020, at 10 mg of lutein and 2 mg of zeaxanthin, matches the studied dose for skin and eye health, and the brand's skin claims, 2.5 times greater improvement in elastic recovery versus placebo and 10 percent better skin tone clarity, come from the Lutemax ingredient research, not from a trial of this product. The product page shows no citation for those figures. None of these ingredients has been tested together in people, and no trial has tested this combination against plain NMN or NR. The formula is thoughtful. Thoughtful is not the same as proven.

Safety and limitations

NAD+ has no established daily value and no established upper limit, because no regulator has set one. Long-term safety of direct NAD+ supplementation is unknown. The one human study lasted two weeks. The one dropout was a person taking an SSRI who reported worse depressive symptoms, so anyone on an antidepressant should talk to their clinician before trying this. The 20 mg of caffeine is small, but it matters for people who are caffeine sensitive, anxious, or prone to poor sleep, especially if the packet is taken late in the day. Niacin at 7 mg is well below flushing doses. A 2020 review of NAD+ precursor research also raised a theoretical concern that chronically raising NAD+ could support tumour metabolism, which is why anyone with a history of cancer should discuss this with their clinician. There is no safety data in pregnancy or breastfeeding, so avoid it there. And the biggest limitation is the one this whole review keeps returning to. No trial has shown that this product raises NAD+ in people, and no trial has shown that raising NAD+ this way changes any health outcome.

Price and value

One box lists at $77. A one-time purchase is $61.60 with the sitewide 20 percent off banner running at the time of writing. The first subscription box is $55.44, renewing at $69.30 a box. The 90-day plan is $49.28 a box. Here is the catch. The brand page never prints how many packets are in a box. The 30-day subscription delivers one box every 30 days at one packet a day, which points to 30 packets, and that is the figure the math below uses. Retailers sell 12-packet and 26-packet boxes, so check the box you are buying. On the inferred 30-packet box, one-time purchase is about $2.05 a packet, the first subscription box is about $1.85 a packet, the renewal is about $2.31 a packet, and the 90-day plan is about $1.64 a packet. At retail, a 12-packet box costs $33.88 to $34.99, about $2.82 to $2.92 a packet. Prices change, so check the current price on the product page. The page shows a rating of 4.4 out of 5 from 263 reviews, with 84 percent saying they would recommend it. There is no discount code for Cymbiotika. If you want to look at it, here is my affiliate link: https://shop.cymbiotika.com/SFVM9DY9. The link is the way to find the product.

Compare that with the precursors. Plain NMN or NR capsules with human trial data behind them cost roughly $1 to $2 a day at the doses used in trials. So this product is not dramatically more expensive than the proven alternatives. It is more expensive per proven result, because it has none of its own. Worth it if you want the convenience of a single packet, the multi-pathway formula, and the skin ingredients in one dose, and you understand you are paying for a hypothesis. Not worth it if you want the best-evidenced way to raise NAD+, because that is NMN or NR, and they cost about the same.

The verdict

Of the four Cymbiotika products covered in this series so far, this one has the weakest evidence. The D3 product had a real head-to-head trial of the exact product. Glutathione, vitamin C, and magnesium each have their own absorption or outcome data. Liposomal NAD+ has one small, short, company-funded study of a different product at more than three times the dose, and nothing else. The formula is well thought out, the supporting ingredients each have a mechanism, and the price is in line with the precursors. But a thoughtful formula is a hypothesis, and this hypothesis has not been tested. If Cymbiotika runs a randomised, placebo-controlled trial of this exact product at 300 mg and measures intracellular NAD+, that would change the verdict. Until then, the honest summary is that liposomal NAD+ might raise your NAD+, the precursors probably will, and neither has been shown to make you healthier.

FAQ

Does liposomal NAD+ actually raise NAD+ levels?

The only published human study says it can, at 1,000 mg a day for two weeks, in 14 people, with no placebo group and funding from the company that made the product tested. Intracellular NAD+ rose about 64 percent. Nobody has tested the 300 mg dose in this product, and nobody has tested this brand's formula in people.

Is Cymbiotika NAD+ better than NMN or NR?

There is no trial comparing them, so nobody knows. NMN and NR have the human evidence: dozens of trials showing they raise blood NAD+ markers, at doses of 250 to 900 mg a day. Liposomal NAD+ has one small study at 1,000 mg. On evidence alone, the precursors win.

How much NAD+ is in each packet, and is 300 mg enough?

Each 10 mL packet has 300 mg of NAD+, plus 1,000 mg of TMG, 50 mg of apigenin, 20 mg of caffeine, 7 mg of niacin, and 10 mg of lutein with 2 mg of zeaxanthin. Whether 300 mg is enough is unanswered, because the only study used 1,000 mg.

What do the niacin, TMG, apigenin, and caffeine do?

Niacin is a direct NAD+ precursor. TMG donates methyl groups that NAD+ metabolism uses up. Apigenin blocks CD38, an enzyme that drains NAD+ as we age, at least in mice. Caffeine, at 20 mg, is about a fifth of a cup of coffee and is the most likely source of the day-one energy feeling. None of this has been tested in this combination in people.

Can liposomal NAD+ improve energy, skin, or brain function?

No trial has shown it. The skin claims on the product page, 2.5 times greater improvement in elastic recovery and 10 percent better skin tone clarity, come from the Lutemax ingredient research, not from a trial of this product. Energy on day one is most plausibly the 20 mg of caffeine. Brain and longevity benefits are unproven for every NAD+ approach, including the precursors.

Is liposomal NAD+ safe? Who should avoid it?

Short-term use appears well tolerated in the one small study, but long-term safety is unknown. Talk to your clinician first if you take an antidepressant, because one SSRI user dropped out of the study with worse depressive symptoms. The same applies if you have a history of cancer, are pregnant or breastfeeding, or are sensitive to caffeine.

How much does it cost per day?

On the brand site, one box lists at $77, with a one-time price of $61.60. The packet count is not printed on the page, but the 30-day plan points to 30 packets, which works out to about $2.05 a packet one-time, about $1.85 on the first subscription box, and about $1.64 on the 90-day plan. The subscription renews at $69.30 a box, about $2.31 a packet. Retail 12-packet boxes cost about $2.82 to $2.92 a packet. There is no discount code for Cymbiotika. The affiliate link on this page is the way to find the product: https://shop.cymbiotika.com/SFVM9DY9.

Sources

  1. Blair E, Miller A, McDonald R. Increased intracellular NAD+ levels via oral supplementation with a novel liposomal delivery method: a non-randomized crossover study. Naturopathic Doctor News and Review, 2026 (published Mar 4, 2026). 14 participants, 1,000 mg CELLg8 liposomal NAD+ daily for 2 weeks, intracellular NAD+ up about 64 percent (p<0.01). No placebo group, no randomisation, funded by CELLg8.
  2. Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews, 2026. PMID 41655607. 113 studies (33 human, 80 rodent), 2010 to November 2025. Oral NR and NMN consistently raised NAD+ metabolites, functional outcomes mixed or null, clinical efficacy for anti-aging or wellness not established.
  3. Yi L et al. Efficacy and safety of nicotinamide mononucleotide supplementation in healthy adults. GeroScience, 2023. doi:10.1007/s11357-022-00705-1. 80 adults, NMN 300, 600, or 900 mg daily for 60 days, blood NAD+ rose dose-dependently, walking distance improved at 600 and 900 mg.
  4. Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 2021. doi:10.1126/science.abe9985. NMN 250 mg daily for 10 weeks.
  5. Yang et al. Meta-analysis of randomized trials of oral NMN, 2026. 15 parallel randomised trials, NMN 250 to 2,000 mg daily for 14 days to 24 weeks. No significant effect on body weight, fasting glucose, HbA1c, blood lipids, or systolic blood pressure. Diastolic pressure fell slightly.
  6. Massudi H et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One, 2012. doi:10.1371/journal.pone.0042357. NAD+ levels decline with age in human plasma and tissue.
  7. Camacho-Pereira J et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism, 2016. doi:10.1016/j.cmet.2016.05.006. CD38 rises with age and consumes NAD+.
  8. Escande C et al. Flavonoid apigenin is an inhibitor of the NADase CD38: implications for cellular NAD+ metabolism, anti-aging, and metabolic syndrome. Diabetes, 2013. Apigenin inhibited CD38 and raised NAD+ in mice. No human dose established.
  9. Purpura M et al. Liposomal delivery enhances absorption of vitamin C into plasma and leukocytes: a double-blind, placebo-controlled, randomized trial. European Journal of Nutrition, 2024. doi:10.1007/s00394-024-03487-8. Liposomal vitamin C reached a 27 percent higher peak than regular vitamin C. Shows liposomes can help some molecules, not that they help NAD+.
  10. Cymbiotika. Liposomal NAD+ product page. https://cymbiotika.com/en-us/products/nad (accessed Nov 14, 2026, for product facts, price, rating, and Supplement Facts).

This article is for general information only and is not medical advice. It reports on published studies and does not recommend any supplement, dose, or treatment. Talk to your clinician before starting a new supplement, especially if you take an antidepressant, have a history of cancer, or are pregnant or breastfeeding.

Not sure where to start?

Take the 30-second protocol finder

Pick your biggest concern — get 3 vetted products with discount codes built in.

Find my protocol